While the research to date indicates that single-chain TGF-β traps have promising therapeutic potential, their lack of specific tumor targeting, their short circulating half-lives and the encountered inherent manufacturability challenges, are significant challenges that prevent their development towards a potential clinical application. This evidence concerns the gene TGFB1 and neoplasm.